

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting***  
September 13, 2023

**QUESTIONS**

---

1. **DISCUSSION:** Discuss the magnitude and clinical meaningfulness of patisiran's treatment effect on 6-minute walk test.
2. **DISCUSSION:** Discuss the magnitude and clinical meaningfulness of patisiran's treatment effect on the Kansas City Cardiomyopathy Questionnaire – Overall Summary Score.
3. **DISCUSSION:** Discuss whether patisiran has other established clinical benefits for the treatment of transthyretin amyloidosis (ATTR) cardiomyopathy.
4. **DISCUSSION:** Discuss whether there is a clinically meaningful benefit of patisiran in patients with ATTR cardiomyopathy who are also receiving tafamidis. Also discuss whether there is a patient population that would benefit from patisiran monotherapy without tafamidis, taking into account that tafamidis is approved for reducing cardiovascular mortality and cardiovascular-related hospitalization in ATTR cardiomyopathy.
5. **DISCUSSION:** Discuss whether patisiran has safety issues of concern for the treatment of ATTR cardiomyopathy.
6. **VOTE:** Do patisiran's benefits outweigh its risks for the treatment of ATTR cardiomyopathy?

Provide rationale for your vote.

If you voted yes, describe the patient population, the clinically meaningful benefit, and how the clinical meaningfulness was established.

If you voted no, provide recommendations for additional data and/or analyses that may support a positive benefit/risk assessment of patisiran for the treatment of ATTR cardiomyopathy.